Prior to its presentation at the annual JPMorgan Healthcare conference, MAKO Surgical (MAKO) released some limited information about its fourth-quarter results. While MAKO avoided the big miss that some investors had feared, and system placement performance was in line with expectations, utilization continues to be a meaningful concern for this company.
Q4 Data - Placements Okay, Procedures Less So
For the fourth quarter of 2012, MAKO Surgical reported that it had sold 15 RIO systems around the world, basically matching Wall Street expectations. While two of the sales were overseas and appear to have a meaningful deferred revenue recognition treatment, that's a quibble at this point. It's worth noting, though, that while this performance matched expectations, the full-year...
Only subscribers can access this article, which is part of the PRO research library covering 3,589 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: